NCT01611467View on ClinicalTrials.gov

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 1, 2012

Primary Completion Date

July 1, 2012

Study Completion Date

July 1, 2012

Conditions
Safety and Pharmacokinetics in Healthy Volunteer Subjects
Interventions
DRUG

CC-223

20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution

DRUG

CC-223

20-mg oral CC-223 tablet under fasting or fed conditions

Trial Locations (1)

53704

Covance Research Unit, Inc, Madison

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01611467 - A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects | Biotech Hunter | Biotech Hunter